Lantus Solostar, 100 Units/mL Subcutaneous Solution + Insulin RinGlar, 100 Units/mL Subcutaneous Solution

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 1

Conditions

Diabetes Mellitus, Type 1, Diabetes Mellitus

Trial Timeline

Jul 4, 2018 → May 15, 2019

About Lantus Solostar, 100 Units/mL Subcutaneous Solution + Insulin RinGlar, 100 Units/mL Subcutaneous Solution

Lantus Solostar, 100 Units/mL Subcutaneous Solution + Insulin RinGlar, 100 Units/mL Subcutaneous Solution is a phase 3 stage product being developed by GEROPHARM for Diabetes Mellitus, Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT04022993. Target conditions include Diabetes Mellitus, Type 1, Diabetes Mellitus.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04022993Phase 3Completed